Neurodegenerative disease Archives

News and Trends 8 Dec 2016

Meet the Newest ALS Pioneer Company from Switzerland

AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist. The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. […]

December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

CRISPR meets RNAi: a whole new Targeted Therapy

Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Oct 2016

Meet the First Biotech to Jump on Autophagy After This Years’ Nobel Prize

Just after the Nobel Prize was awarded to the study of autophagy, PhoreMost announces a collaboration to target the process in neurodegenerative diseases. PhoreMost is a drug discovery company that focuses on finding ‘undruggable’ targets, such as the KRAS cancer gene. Now, the company has announced a collaboration with the University of Cambridge to start working […]

October 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2016

World Mental Health Day: How is Biotech Helping the Cause?

Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some of the latest technologies that address these conditions. Yesterday, October 10th, was World Mental Health Day: it is dedicated to raising awareness of neurological and mental disorders […]

October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

synapses neurons alzheimers Bruce Rolff fi

News and Trends 27 Sep 2016

Another “Almost” against Alzheimers: Lundbeck’s Phase III Flop

Alzheimer’s Disease is the most common form of dementia, affecting 15M people across the world. With the most recent failure of idalopirdine, a cure will remain elusive for now. As Derek Lowe observes, “Alzheimers therapies have, for the most part, been a cliff over which people push bales of money.” Unfortunately, the late-stage failure of […]

September 27, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 14 Sep 2016

This French Startup brings Gene Therapy to Neurodegenerative Diseases

There were many exciting developments for CNS disease treatments last year, and now a French biotech is winding up to add gene therapy to the mix. BrainVectis just closed its Series A round with €1M. Paris-based BrainVectis wants to apply some of the hottest technology in biotech, gene therapy, to neurodegenerative disease, and it just […]

September 14, 2016 - 3 minutesmins - By Evelyn Warner

taurx tau protein tangles biotech alzheimers

News and Trends 28 Jul 2016

World first Drug to ‘dissolve’ Tau-tangles in Alzheimer’s has Phase III Results

The much-anticipated results of TauRx’s Phase III trial for Alzheimer’s disease have finally been disclosed. Despite some complicated effects, this could be the first available working therapy for Alzheimer’s patients. According to the WHO, Alzheimer’s disease is the cause of up to 70% of dementia cases, which translates to over 30 million patients worldwide. As the world population ages, Alzheimer’s […]

July 28, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Jul 2016

Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

This week we’re exchanging a very warm and welcoming country for another. We are heading to Barcelona, the wonderful capital of Catalunya in Spain, to visit Oryzon, our Biotech of The Week and maybe (just maybe) have a little swim in the Barceloneta beach. City: Barcelona (Spain) Founded: 2000 Employees: 35 Financial Data: €81.50M Market Cap (Bolsa de […]

July 22, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 23 Jun 2016

Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins, thought to be the main cause of this major disease. Alzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients […]

June 23, 2016 - 2 minutesmins - By Denise Neves Gameiro

interview biotrinity labiotech dementia fund

News and Trends 28 Apr 2016

Interviewing the CSO of the newly €90M fund willing to finally tackle Dementia

I had the chance to talk with Tetsuyuki Maruyama, the CSO of the relatively new Dementia Discovery Fund – our final interview for #BioTrinity2016 in London. The high risk nature of doing trials for Dementia patients means in the past the market for this area of Neurodegenerative disease has been tough. However, the need for […]

April 28, 2016 - 1 minutemin - By Philip Hemme

world parkinson parkinsons disease awareness day CNS biotech neurological neurodegenerative

News and Trends 11 Apr 2016

It’s World Parkinson’s Disease Day! #EndParkinsons

Today (April 11th) is the birthday of the memorable Dr James Parkinson, who discovered this major neurodegenerative disease. So what is Parkinson’s Disease, and who is researching it? First described in 1817 by James Parkinson, Parkinson’s Disease (PD) is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s. Since PD mainly affects […]

April 11, 2016 - 4 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us